March 2025 Volume 21, Issue 1
Volume 21, Issue 1 | March 2025
March 2025
In this Issue
Women's Health
Rebuilding vaginal health with beneficial bacteria
Bacteria from healthy vaginas show promise in protecting women from pathogens, but advancing their development requires more funding and research.
A new migraine medication is on the horizon
Lundbeck Therapeutics is testing a monoclonal antibody that targets a novel neuropeptide in a Phase 2b clinical trial.
A new drug-device combination for non-hormonal contraception
Sabrina Johnson at Daré Bioscience is redefining contraception with Ovaprene, a non-hormonal, monthly option for safe and effective birth control.
Overcoming delivery hurdles, IL-12 tackles ovarian cancer
A targeted interleukin-12 gene therapy plus chemotherapy increased survival in advanced ovarian cancer, setting the stage for a new first-line drug.Metabolic Disease
Finding new strategies to treat Pompe disease
Enzyme replacement therapy has been the mainstay of Pompe disease. New and emerging therapies may provide more options for patients.
Illuminating the full side effect profile of GLP-1 drugs
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.Microbiology
Diagnostics for faster antimicrobial susceptibility testing
New phenotypic methods can help identify the best antibiotic to treat sepsis, UTIs, and other bacterial infections.
Phages return CRISPR to its microbial roots
Virus-inspired delivery methods enable gene editing of dysregulated microbes.
Antibiotics disrupt the beneficial mucus barrier lining the gut
Antibiotics target bacteria, but new work in mice shows they also harm the mucus layer that protects the intestinal lining from microbes.Editors Insight
Editorial: Of snakes and science communication
A close encounter with a venomous critter sparked insight for communicating science in times of stress.Cancer
Targeting aneuploidy to treat cancer
Most cancer cells have the wrong number of chromosomes, known as aneuploidy. Scientists are finding ways to target this flaw with new treatments.
A dual-threat cancer drug takes aim at resistance mechanisms
Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies.
Autophagy and cancer: friends or foes?
Autophagy in cancer is a double-edged sword: It protects cells from malignant transformation, but once tumors form, it helps them thrive.
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
